ArticlePsycho-oncology2025
Prostate Cancer Specialist Nursing Program: A Social Return on Investment Analysis Value for Money of the Prostate Cancer Specialist Nursing Program.
Article in Psycho-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundIn Australia, Prostate cancer (PCa) has a high survival rate (96%) meaning men with PCa may live with the impact of the disease for many years, even decades. The Prostate Cancer Foundation of Australia (PCFA) manages two Prostate Cancer Specialist Nursing (PCSN) programs: (1) A health service-based program and (2) A telenursing service. There is a paucity of economic evidence regarding the benefits of these programs so Social Return on Investment (SROI) methodology was used to determine social value and return on investment.
methodsA SROI economic evaluation model was developed in consultation with the PCSN team augmented with published evidence to identify the costs and outcomes, and estimate the benefits associated with the delivery of the PCSN program over 2 years. Attribution, dead weight loss and discounting were calculated and sensitivity analyses were conducted to test the rigour of the model.
resultsThe value generated by the PCSN programs over the 2-year period resulted in a SROI ratio of 1:1.62 for the health service-based PCSN program, indicating that for every dollar invested, a return of AUD $1.62 was obtained. The SROI ratios for the Telenursing program and the combined programs were 1:2.34 and 1:1.65, respectively.
conclusionOur study provides evidence that further expansion of the PCSN program is likely to have a positive return on investment and benefit the 250,000 men currently living with PCa in Australia. Findings such as these are important in informing cancer care policy and funding decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.